Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer’s Disease
Sponsor:Neurobehavioral Systems, Inc.Brief Summary: The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to…
[searchandfilter fields="search,category" post_types="post"]
A Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer’s Type
Sponsor:Axsome Therapeutics, Inc.Brief Summary: This is a multi-center, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of…
Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions
Sponsor:Thomas Advanced Medical LLCBrief Summary: This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for…
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer’s Disease With Validation of Remote Neuropsychological Assessments
Sponsor:Eli Lilly and CompanyBrief Summary: The main goals of this study are to further determine whether the study drug donanemab…
A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer’s Disease
Sponsor:Washington University School of MedicineBrief Summary: The purpose of this study is to assess the safety, tolerability, biomarker and cognitive…
Extending Independence and Quality of Life for People With Alzheimer’s Disease or Dementia Through Telehealth Program Delivery
Sponsor:University of California, San FranciscoBrief Summary: To determine whether Moving Together improves quality of life in people with memory loss…
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer’s Disease
Sponsor:Janssen Research & Development, LLCBrief Summary: The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus…
Lifestyle Intervention for Early Alzheimer’s Disease
Sponsor:Preventive Medicine Research InstituteBrief Summary: The objective of this study is to determine if comprehensive lifestyle changes may slow, stop,…
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer’s Disease
Sponsor:Alector Inc.Brief Summary: A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in…
Opicapone Treatment Initiation Open-Label Study
Sponsor:Neurocrine BiosciencesBrief Summary: This is an observational study to describe the treatment patterns and clinical outcomes observed with use of…
